Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis

(MedPage Today) -- Off-label rituximab was noninferior to ocrelizumab (Ocrevus) in people with newly diagnosed relapsing multiple sclerosis (MS) and recent disease activity, the phase III OVERLORD-MS trial showed.
At 2 years, the estimated probability...